MR Scanning of Very Young Children With Severe Developmental Disorders

This study has been completed.

Sponsor:

Collaborators:

Netherlands Organisation for Scientific Research

The Dutch Brain Foundation

Information provided by:

UMC Utrecht

ClinicalTrials.gov Identifier:

NCT00156221

First received: September 8, 2005

Last updated: NA

Last verified: September 2005

History: No changes posted

Purpose

The specific is to study the MR morphologic and spectroscopic brain correlates and predictors of development in children with severe developmental disorders (autistic spectrum disorders and/or mental retardation and/or language disorders). Given the frequently observed association of autism with known medical conditions, particularly in cases with comorbid mental retardation and in cases with atypical autism (Rutter et al., 1994; Gillberg, 1995), children with suspected autism or related developmental disorders will be asked to participate in an extensive state of the art laboratory work-up which includes T1 and T2 weighted MRI of the brain. MRI data will be analyzed both qualitatively, looking for focal abnormalities and degree of myelination, and quantitatively, measuring volumes of total brain, cerebellum, ventricles and grey and white matter. For research purposes, the work-up will be supplied with proton Magnetic Resonance Spectroscopy (MRS) of the brain. This data set provides the opportunity to chart brain-behavior relationships in young children with suspected autism and related PDD cross-sectionally.

Condition
Autism Mental Retardation Language Disorder


Study Type:	Observational
Study Design:	Observational Model: Natural History Time Perspective: Cross-Sectional Time Perspective: Retrospective/Prospective
Official Title:	MR Scanning of Very Young Children With Severe Developmental Disorders (Autistic Spectrum Disorders and/or Mental Retardation and/or Language Disorders)

Resource links provided by NLM:

Genetics Home Reference related topics: CASK-related intellectual disability SYNGAP1-related intellectual disability autism spectrum disorder

MedlinePlus related topics: Developmental Disabilities

U.S. FDA Resources

Further study details as provided by UMC Utrecht:


Study Start Date:	September 2000
Estimated Study Completion Date:	September 2005

Eligibility


Ages Eligible for Study:	18 Months to 7 Years (Child)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age 18 months to 7 years
Diagnosis of autism spectrum disorder, a language disorder or mental retardation

Exclusion Criteria:

Significant motor or sensory impairment
Major physical abnormalities
History of serious head injury
Identifiable neurologic disorder
Metal implants
Contraindication for MRI

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00156221

Locations


Netherlands
UMC Utrecht
Utrecht, Netherlands, 3508 GA

Sponsors and Collaborators

UMC Utrecht

Netherlands Organisation for Scientific Research

The Dutch Brain Foundation

Investigators


Study Chair:	Herman van Engeland, PhD, MD	UMC Utrecht
Principal Investigator:	Mijke Zeegers, Msc	UMC Utrecht

More Information


ClinicalTrials.gov Identifier:	NCT00156221 History of Changes
Other Study ID Numbers:	METC UMC Utrecht 99/184
Study First Received:	September 8, 2005
Last Updated:	September 8, 2005

Keywords provided by UMC Utrecht:


Autism MRI Developmental Disorders

Additional relevant MeSH terms:


Language Disorders Disease Developmental Disabilities Intellectual Disability Pathologic Processes Neurodevelopmental Disorders	Mental Disorders Neurobehavioral Manifestations Neurologic Manifestations Nervous System Diseases Signs and Symptoms Communication Disorders

ClinicalTrials.gov processed this record on August 18, 2017

To Top